# US 2023/0069712 A1 · Compounds for the induction of antigen-specific immune tolerance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069712 A1
- Document ID: US20230069712A1
- Status: Published application
- Kind: A1
- Application number: 17/753,603
- Filed: 2020-09-18
- Published: 2023-03-02
- Earliest claimed: 2019-09-20
- Assignees: Anokion SA
- Applicants: Anokion SA
- Inventors: Stephan Kontos; Dilrukshi Vitharana; Sergey A. Isarov
- Web page: https://patentgrep.com/patent/US20230069712A1

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 39/35: Allergens
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- A61K 2039/627: {characterised by the linker}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds for the induction of antigen-specific immune tolerance in a subject, the compounds comprising an antigen, a polymeric linker and a liver targeting moiety, wherein the polymeric linker comprises a terminal end unit lacking each of a dithioester and a dithiobenzoate and wherein the terminal end unit confers improved stability to the compound when in solution.

## Claims

### Claim at position 1

-82. (canceled)

### Claim 83

A compound for the induction of antigen-specific immune tolerance in a subject, the compound comprising:
an antigen to which tolerance is desired or a tolerogenic portion thereof;
wherein the antigen to which tolerance is desired, when presented alone to the subject is capable of inducing an unwanted immune response in the subject;
a polymeric linker that does not include a dithiobenzoate, trithiocarbonate, or a xanthate, the linker comprising:
a copolymer or a random copolymer, wherein the copolymer or random copolymer comprises of first acrylyl unit and a second acrylyl unit, the first acrylyl unit comprising a first C-amido or C-carboxy functionality and the second acrylyl unit comprising a second C-amido or C-carboxy functionality;
wherein the second C-amido or C-carboxy functionality is conjugated to an aliphatic group, an alcohol, or an aliphatic alcohol;
wherein the polymeric linker is bonded to the antigen to which tolerance is desired or tolerogenic portion thereof via a disulfide bond or a disulfanyl ethyl ester,
wherein the disulfide bond or the disulfanyl ethyl ester are each configured to be cleaved upon administration of the compound to the subject and to release the antigen to which tolerance is desired or tolerogenic portion thereof from the polymeric linker;
wherein the polymeric linker comprises an end-capping group that improves the stability of the compound in solution by at least 20% as compared to a linker that includes a dithiobenzoate-containing, trithiocarbonate containing, or a xanthate-containing end-capping group; and
a liver-targeting moiety;
wherein the liver targeting moiety is connected to the first acrylyl unit through the first C-amido or C-carboxy functionality and a polyether.

### Claim 84 (depends on 83)

The compound of claim 83, wherein the antigen to which tolerance is desired is a food antigen or a self antigen.

### Claim 85 (depends on 84)

The compound of claim 84, wherein the antigen to which tolerance is desired is a food antigen, and wherein the food antigen is associated with Celiac disease.

### Claim 86 (depends on 83)

The compound of claim 83, wherein the antigen to which tolerance is desired comprises one or more of SEQ ID NO. 55, SEQ ID NO. 54, SEQ ID NO. 56, or SEQ ID NO. 57.

### Claim 87 (depends on 83)

The compound of claim 83, wherein the liver targeting moiety comprises one or more of N-acetylgalactosamine, galactose, galactosamine, glucose, glucosamine, and N-acetylglucosamine.

### Claim 88 (depends on 87)

The compound of claim 87, wherein the liver-targeting moiety comprises N-acetylgalactosamine, wherein the antigen to which tolerance is desired comprises one or more of SEQ ID NO. 55, and wherein, when in a solution of 10 mM sodium acetate and 274 mM sorbitol at a compound concentration of 1 mg/mL, at a temperature of 23° C. to 27° C., the compound degrades less than 2.0% over a period of 28 days.

### Claim 89 (depends on 84)

The compound of claim 84, wherein the antigen to which tolerance is desired is a self antigen, and wherein the self antigen is associated with multiple sclerosis.

### Claim 90 (depends on 83)

The compound of claim 83, wherein the antigen to which tolerance is desired comprises one or more of SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 43, SEQ ID NO. 44, SEQ ID NO. 45, or SEQ ID NO. 46.

### Claim 91

A compound for the induction of antigen-specific immune tolerance in a subject, the compound comprising:
an antigen to which tolerance is desired;
wherein the antigen to which tolerance is desired, when presented alone to the subject is capable of inducing an unwanted immune response in the subject;
a polymeric linker comprising:
a copolymer comprising a first acrylyl unit and a second acrylyl unit, the first acrylyl unit comprising a first C-amido or C-carboxy functionality and the second acrylyl unit comprising a second C-amido or C-carboxy functionality;
wherein the second C-amido or C-carboxy functionality is conjugated to an aliphatic group, an alcohol, or an aliphatic alcohol;
wherein the polymeric linker is bonded to the antigen to which tolerance is desired via a disulfide bond or a disulfanyl ethyl ester;
wherein the polymeric linker comprises a terminal end unit lacking each of a dithioester and a dithiobenzoate (DTB) and wherein the terminal end unit confers improved stability to the compound when in solution; and
a liver-targeting moiety; and
wherein the liver targeting moiety is connected to the first acrylyl unit through the first C-amido or C-carboxy functionality and a polyether.

### Claim 92 (depends on 91)

The compound of claim 91, wherein the antigen to which tolerance is desired is associated with Celiac disease.

### Claim 93 (depends on 91)

The compound of claim 91, wherein the food antigen is selected from the group consisting of high molecular weight glutenin, low molecular weight glutenin, alpha-, gamma- and omega-gliadin, hordein, secalin, avenin, a tolerogenic portion of any of said antigens.

### Claim 94 (depends on 91)

The compound of claim 91, wherein the antigen to which tolerance is desired is associated with food allergy, and wherein the food antigen is selected from the group consisting of conarachin (Ara h 1), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), 31 kda major allergen/disease resistance protein homolog (Mal d 2), lipid transfer protein precursor (Mal d 3), major allergen Mal d 1.03D (Mal d 1), α-lactalbumin (ALA), lactotransferrin, actinidin (Act c 1, Act d 1), phytocystatin, thaumatin-like protein (Act d 2), kiwellin (Act d 5), ovomucoid, ovalbumin, ovotransferrin, and lysozyme, livetin, apovitillin, vosvetin, 2S albumin (Sin a 1), 1 lS globulin (Sin a 2), lipid transfer protein (Sin a 3), profilin (Sin a 4), profilin (Api g 4), high molecular weight glycoprotein (Api g 5), Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform, high molecular weight glutenin, low molecular weight glutenin, alpha-, gamma- and omega-gliadin, hordein, secalin, avenin, major strawberry allergy Fra a 1-E (Fra a 1), profilin (Mus xp 1), and a tolerogenic portion of any of said antigens.

### Claim 95 (depends on 91)

The compound of claim 91, where the antigen to which tolerance is desired is associated with an autoimmune disease, and wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, Type I diabetes, rheumatoid arthritis, vitiligo, uveitis, pemphigus vulgaris, neuromyelitis optica, Goodpasture's Disease, Parkinson's disease, myasthenia gravis, celiac disease, and anti-neutrophil cytoplasmic antibody-associated vasculitis.

### Claim 96 (depends on 95)

The compound of claim 95, where the antigen to which tolerance is desired comprises one or more of a tolerogenic portion of myelin oligodendrocyte glycoprotein, a tolerogenic portion of myelin basic protein, and a tolerogenic portion of.

### Claim 97 (depends on 95)

The compound of claim 95, wherein the antigen to which tolerance is desired comprises one or more of a tolerogenic portion of insulin, a tolerogenic portion of proinsulin, a tolerogenic portion of preproinsulin, a tolerogenic portion of glutamic acid decarboxylase-65 (GAD-65), a tolerogenic portion of GAD-67, and a tolerogenic portion of insulinoma associated protein 2 (IA-2).

### Claim 98 (depends on 95)

The compound of claim 95, wherein the antigen to which tolerance is desired comprises one or more of a tolerogenic portion desmoglein-3, a tolerogenic portion of desmoglein-1, and a tolerogenic portion of desmoglein-4.

### Claim 99 (depends on 95)

The compound of claim 95, wherein the antigen to which tolerance is desired comprises one or more of a tolerogenic portion of an acetylcholine receptor, a tolerogenic portion of muscle-specific kinase (MuSK), and a tolerogenic portion of lipoprotein receptor-related protein (LRP4).

### Claim 100

A compound for the induction of antigen-specific immune tolerance in a subject, the compound comprising an antigen to which tolerance is desired, a polymeric linker comprising a polymeric portion, and a liver targeting moiety;
wherein the linker is bonded to the antigen via a disulfide bond or a disulfanyl ethyl ester;
wherein the disulfide bond or the disulfanyl ethyl ester are each configured to be cleaved upon administration of the compound to the subject and to release the antigen from the polymeric linker;
wherein the polymeric linker comprises a terminal end unit lacking each of a dithioester and a dithiobenzoate (DTB) and wherein the terminal end unit confers improved stability to the compound when in solution.

### Claim 101 (depends on 100)

The compound of claim 100, wherein the antigen to which tolerance is desired comprises one or more of SEQ ID NO. 55, SEQ ID NO. 54, SEQ ID NO. 56, or SEQ ID NO. 57 and the liver targeting moiety comprises one or more of N-acetylgalactosamine, galactose, galactosamine, glucose, glucosamine, and N-acetylglucosamine.

### Claim 102 (depends on 100)

The compound of claim 100, wherein the antigen to which tolerance is desired comprises one or more of and the liver targeting moiety comprises one or more of N-acetylgalactosamine, galactose, galactosamine, glucose, glucosamine, and N-acetylglucosamine.
